CancerVax
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
351 Paseo Nuevo Pmb 2, Santa Barbara, Ca...Phone Number
(805) 356-1810Website
www.cancervax.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CancerVax
CancerVax is a pre-clinical biotech company focused on developing a revolutionary Universal Cancer Treatment Platform that utilizes the body's immune system to target and kill cancer cells by disguising them as common diseases like measles. Their innovative approach aims to simplify cancer treatment to a single injection, addressing the significant challenge of cancer cell recognition by the immune system. The company collaborates with leading experts and partners in biotechnology to enhance its therapeutic offerings. CancerVax targets a wide range of clients, including pharmaceutical and biotech companies, as well as research organizations involved in cancer treatment and immunotherapy.Explore more
CancerVax Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CancerVax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if CancerVax is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once CancerVax has new funding data
Click to see if CancerVax had a recent Job posting/layoffs
Check if CancerVax has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on CancerVax recently announced quarterly report
CancerVax, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at CancerVax
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when CancerVax launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to CancerVax
Compare insights from companies similar to CancerVax, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CancerVax is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CancerVax is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CancerVax.
CancerVax financials insights
Gather financial insights about CancerVax, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$10M
CancerVax Tech Stack
A closer look at the technologies used by CancerVax
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Funding
New Hire
Executive Move
New Hire
Executive Move
CancerVax News & Media
CancerVax Reports Successful Initial Mouse Study with Breakthrough Results
First biodistribution study of the Company’s novel targeted lipid nanoparticle achieved systemic circulation with the potential to target many types of cancer First biodistribution study of the Company’s novel targeted lipid nanoparticle achieved systemic circulation with the potential to target many types of cancerBiotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platform Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platformWorld-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platformCancerVax Reviews Major Scientific and Strategic Milestones Achieved in 2025
Year-End Recap Highlights Breakthrough Discoveries, Platform Advancements, and Strengthened Scientific Leadership Year-End Recap Highlights Breakthrough Discoveries, Platform Advancements, and Strengthened Scientific Leadership
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding CancerVax
Sign Up For FreeTo access detailed company insights
CancerVax is a pre-clinical biotech company focused on developing a revolutionary Universal Cancer Treatment Platform that utilizes the body's immune system to target and kill cancer cells by disguising them as common diseases like measles. Their innovative approach aims to simplify cancer treatment to a single injection, addressing the significant... Read More
